FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
- Written by PR Newswire
IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today...
